Aerie Pharmaceuticals to Participate in Several Conferences in November

Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that company management will present an overview of the company at the following conferences in November.

  • Ophthalmology Innovation Summit (OIS) at the American Society of Ophthalmology (AAO) 2015
    • Presenter: Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board
    • Presentation Date: Thursday, November 12, 2015
    • Presentation Time: 4:00pm P.T.
    • Location: Las Vegas, NV
  • Stifel Nicolaus Annual Healthcare Conference
    • Presenter: Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board
    • Presentation Date: Tuesday, November 17, 2015
    • Presentation Time: 3:00pm E.T.
    • Location: New York, NY
  • Jefferies Autumn 2015 Global Healthcare Conference
    • Presenter: Richard Rubino, Chief Financial Officer
    • Presentation Date: Thursday, November 19, 2015
    • Presentation Time: 8:00am G.M.T.
    • Location: London, UK

In addition, Mr. Rubino will be attending the Brean Capital 2015 Life Sciences Summit on Monday, November 16, 2015 in New York, NY.

The Stifel Nicolaus Annual Healthcare Conference and Jefferies Autumn 2015 Global Healthcare Conference presentations will be webcast live and may be accessed by visiting Aerieā€™s website at http://investors.aeriepharma.com/. A replay of each webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie recently reported the successful results of its second Phase 3 registration trial in the United States named Rocket 2, where the primary efficacy endpoint was to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol. Rocket 3, a 12-month safety-only study, is currently in progress, as is a fourth Phase 3 trial for RhopressaTM, named Rocket 4. Aerie expects to file a new drug application for RhopressaTM with the FDA in the third quarter of 2016. Aerie also completed in 2014 a Phase 2b clinical trial in which RoclatanTM met the primary efficacy endpoint, demonstrating the statistical superiority of RoclatanTM to each of its components, and commenced in September 2015 the first Phase 3 registration trial for RoclatanTM, named Mercury 1. Aerie also recently entered into research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University as it further builds its pipeline for future growth.

Contacts:

Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
rrubino@aeriepharma.com
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.